299 related articles for article (PubMed ID: 20386463)
1. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Correale P; Rotundo MS; Del Vecchio MT; Remondo C; Migali C; Ginanneschi C; Tsang KY; Licchetta A; Mannucci S; Loiacono L; Tassone P; Francini G; Tagliaferri P
J Immunother; 2010 May; 33(4):435-41. PubMed ID: 20386463
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
Correale P; Botta C; Rotundo MS; Guglielmo A; Conca R; Licchetta A; Pastina P; Bestoso E; Ciliberto D; Cusi MG; Fioravanti A; Guidelli GM; Bianco MT; Misso G; Martino E; Caraglia M; Tassone P; Mini E; Mantovani G; Ridolfi R; Pirtoli L; Tagliaferri P
J Immunother; 2014 Jan; 37(1):26-35. PubMed ID: 24316553
[TBL] [Abstract][Full Text] [Related]
3. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Correale P; Tagliaferri P; Fioravanti A; Del Vecchio MT; Remondo C; Montagnani F; Rotundo MS; Ginanneschi C; Martellucci I; Francini E; Cusi MG; Tassone P; Francini G
Clin Cancer Res; 2008 Jul; 14(13):4192-9. PubMed ID: 18593999
[TBL] [Abstract][Full Text] [Related]
4. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Correale P; Fioravanti A; Bertoldi I; Montagnani F; Miracco C; Francini G
J Chemother; 2008 Apr; 20(2):278-81. PubMed ID: 18467257
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
Correale P; Cusi MG; Del Vecchio MT; Aquino A; Prete SP; Tsang KY; Micheli L; Nencini C; La Placa M; Montagnani F; Terrosi C; Caraglia M; Formica V; Giorgi G; Bonmassar E; Francini G
J Immunol; 2005 Jul; 175(2):820-8. PubMed ID: 16002679
[TBL] [Abstract][Full Text] [Related]
7. Decreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer.
Hu M; Li K; Maskey N; Xu Z; Peng C; Wang B; Li Y; Yang G
Int J Clin Exp Pathol; 2014; 7(8):4685-94. PubMed ID: 25197340
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
Tenti S; Correale P; Conca R; Pastina P; Fioravanti A
J Chemother; 2012 Aug; 24(4):245-6. PubMed ID: 23040694
[No Abstract] [Full Text] [Related]
10. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
Correale P; Rotundo MS; Botta C; Del Vecchio MT; Ginanneschi C; Licchetta A; Conca R; Apollinari S; De Luca F; Tassone P; Tagliaferri P
Clin Cancer Res; 2012 Feb; 18(3):850-7. PubMed ID: 22142823
[TBL] [Abstract][Full Text] [Related]
11. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
Zaanan A; Taieb J
Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
[TBL] [Abstract][Full Text] [Related]
12. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
14. GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.
Caraglia M; Correale P; Giannicola R; Staropoli N; Botta C; Pastina P; Nesci A; Caporlingua N; Francini E; Ridolfi L; Mini E; Roviello G; Ciliberto D; Agostino RM; Strangio A; Azzarello D; Nardone V; Falzea A; Cappabianca S; Bocchetti M; D'Arrigo G; Tripepi G; Tassone P; Addeo R; Giordano A; Pirtoli L; Francini G; Tagliaferri P
Front Oncol; 2019; 9():1102. PubMed ID: 31781481
[No Abstract] [Full Text] [Related]
15. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations.
Szeponik L; Ahlmanner F; Sundström P; Rodin W; Gustavsson B; Bexe Lindskog E; Wettergren Y; Quiding-Järbrink M
BMC Immunol; 2021 Aug; 22(1):58. PubMed ID: 34407765
[TBL] [Abstract][Full Text] [Related]
17. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
Emile JF; Julié C; Le Malicot K; Lepage C; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Dimet S; Boulagnon-Rombi C; Allard MA; Penault-Llorca F; Bennouna J; Laurent-Puig P; Taieb J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Eur J Cancer; 2017 Sep; 82():16-24. PubMed ID: 28651158
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
19. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Comella P; Massidda B; Filippelli G; Farris A; Natale D; Barberis G; Maiorino L; Palmeri S; Cannone M; Condemi G;
J Cancer Res Clin Oncol; 2009 Feb; 135(2):217-26. PubMed ID: 18719941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
